Catherine M. Szyman - 13 Feb 2024 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, Critical Care
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
13 Feb 2024
Net transactions value
-$2,313,604
Form type
4
Filing time
15 Feb 2024, 17:25:32 UTC
Previous filing
10 Oct 2023
Next filing
23 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $735,000 +20,000 +57% $36.75 54,814 13 Feb 2024 Direct
transaction EW Common Stock Sale $1,729,200 -20,000 -36% $86.46 34,814 13 Feb 2024 Direct F1
transaction EW Common Stock Options Exercise $992,250 +27,000 +78% $36.75 61,814 15 Feb 2024 Direct
transaction EW Common Stock Sale $2,311,654 -27,000 -44% $85.62 34,814 15 Feb 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -20,000 -43% $0.000000 27,000 13 Feb 2024 Common Stock 20,000 $36.75 Direct
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -27,000 -100% $0.000000* 0 15 Feb 2024 Common Stock 27,000 $36.75 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $86.00 to $86.81. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F2 This transaction was executed in multiple trades at prices ranging from $85.44 to $85.83. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person